Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
103 Leser
Artikel bewerten:
(0)

EpiVax and GAIA Vaccine Foundation Celebrate Women's Achievements Throughout History and Across Nations

PROVIDENCE, R.I., March 8, 2018 /PRNewswire/ --EpiVax Inc., ("EpiVax") an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women's Day. The company, founded and led by Dr. Annie De Groot, boasts a female-majority work force and appears multiple times in the Providence Business News Book of Lists for Rhode Island: Top Private Companies (by revenue), Fastest Growing Companies (by revenue-growth percentage) and as a Top Ten Biotechnology Company. In 2017 EpiVax was cited as a Best Places to Work and Rhode Island Innovation '50 on Fire' companies. The company will recognize 20 years of business excellence this May with a relocation of corporate headquarters and office expansion. EpiVax will soon call Rising Sun Mills its new home, in the Olneyville neighborhood of Providence.

EpiVax is an immunology company founded in 1998. We develop and employ extensive analytical capabilities in the field of computational immunology. We assess protein therapeutics for immunogenic risk and design more effective (and safer) vaccines. www.EpiVax.com

EpiVax is dedicated to improving human health at home and abroad. VaxGivesBack, EpiVax's charitable giving committee, is focused on identifying local organizations who will benefit from financial donations or volunteer time. For charitable efforts abroad, De Groot founded the GAIA Vaccine Foundation.

Today, on International Women's day, GAIA Vaccine Foundationofficially launched the second phase of their human Papillomavirus (HPV) prevention campaign in Mali, West Africa. The theme, titled "Our Daughters, Ourselves", focuses on prevention methods across generations. Healthcare clinics will offer free screening and HPV vaccination over 12 months.In the first month of the campaign (Feb 2018), more than 1,600 women were screened and over 200 girls vaccinated. GAIA's programshave alreadysurpassed screening records from 2015, further demonstrating the value of community outreach for prevention.

About GAIA Vaccine Foundation

GAIA, a Rhode Island nonprofit organization with the mission of infectious disease prevention, has developed an innovative method for health communication called the "story-telling cloth". In Mali, the story-telling cloth proved to be an effective tool to raise health awareness: community health workers used the cloth as a visual aid during education sessions, a method that resulted in a 5-fold cervical cancer screening rate increase. During GAIA's 6-month campaign in 2016, over 3,000 women were screened. For more information on all GAIA programs, visit GAIAVaccine.org

About EpiVax
EpiVax is a world leader in the fields of immune engineering and vaccine design. EpiVax's immunogenicity screening tools are used by a global roster of companies to design and optimize therapeutic proteins and vaccineswww.epivax.com

Press Contact:
Sarah Moniz
Business Liaison, EpiVax, Inc.
401.272.2123svessella@epivax.com
CEO/CSOannied@epivax.com

Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.